Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5

被引：10

作者：

Gong, Xudong ^{[1
]}

Wang, Guan ^{[2
]}

Ren, Jing ^{[2
]}

Liu, Zheng ^{[3
]}

Wang, Zhen ^{[2
]}

Chen, Tiantian ^{[2
]}

Yang, Xiaojun ^{[3
]}

Jiang, Xiangrui ^{[2
]}

Shen, Jingshan ^{[2
]}

Jiang, Hualiang ^{[2
]}

Aisa, Haji Akber ^{[1
]}

Xu, Yechun ^{[2
]}

Li, Jianfeng ^{[2
]}

机构：

[1] Chinese Acad Sci, Xinjiang Tech Inst Phys & Chem, Key Lab Xinjiang Indigenous Med Plants Resource U, Urumiqi 830011, Peoples R China

[2] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China

[3] Vitargeta Therapeut Inc, Plainsboro, NJ 08536 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 17期

基金：

国家高技术研究发展计划(863计划); 中国国家自然科学基金;

关键词：

PDE5; inhibitors; 5-Bromopyrimidin-4(3H)-ones; DRUG DEVELOPMENT; PHOSPHODIESTERASE-5; DESIGN;

D O I：

10.1016/j.bmcl.2013.06.062

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The substituents both at the 6-position of the 5-bromopyrimidinone ring and at the 5'-position of the phenyl ring of 5-bromopyrimidin-4(3H)-ones were explored. 5-Bromo-6-isopropyl-2-(2-propoxyphenyl)pyrimidin-4(3H)-one was identified as a new scaffold for potent PDE5 inhibitors. The crystal structures of PDE5/2e and PDE5/10a complexes provided a structural basis for the inhibition of 5-bromopyrimidinones to PDE5. In addition, it was also found that there is a great tolerance for the substitution at the 5'-position of the phenyl ring of 5-bormopyrimidinones and the resulted compound 13a has the highest inhibition activity to PDE5 (IC50, 1.7 nM). (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：4944 / 4947

页数：4

共 17 条

[11] Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules
Sung, BJ
Hwang, KY
Jeon, YH
Lee, JI
Heo, YS
Kim, JH
Moon, J
Yoon, JM
Hyun, YL
Kim, E
Eum, SJ
Park, SY
Lee, JO
Lee, TG
Ro, S
Cho, JM
[J]. NATURE, 2003, 425 (6953) : 98 - 102
[12] Tian G., 2007, [No title captured], Patent No. [EP1961753, 1961753]
[13] Vassilev GN, 2002, OXID COMMUN, V25, P608
[14] Design, Synthesis, and Pharmacological Evaluation of Monocyclic Pyrimidinones as Novel Inhibitors of PDE5
Wang, Guan
Liu, Zheng
Chen, Tiantian
Wang, Zhen
Yang, Huaiyu
Zheng, Mingyue
Ren, Jing
Tian, Guanghui
Yang, Xiaojun
Li, Li
Li, Jianfeng
Suo, Jin
Zhang, Rongxia
Jiang, Xiangrui
Terrett, Nicholas Kenneth
Shen, Jingshan
Xu, Yechun
Jiang, Hualiang
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (23) : 10540 - 10550
[15] Multiple conformations of phosphodiesterase-5 - Implications for enzyme function and drug development
Wang, Huanchen
Liu, Yudong
Huai, Qing
Cai, Jiwen
Zoraghi, Roya
Francis, Sharron H.
Corbin, Jackie D.
Robinson, Howard
Xin, Zhongcheng
Lin, Guiting
Ke, Hengming
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (30) : 21469 - 21479
[16] Utilization of Halogen Bond in Lead Optimization: A Case Study of Rational Design of Potent Phosphodiesterase Type 5 (PDE5) Inhibitors
Xu, Zhijian
Liu, Zheng
Chen, Tong
Chen, TianTian
Wang, Zhen
Tian, Guanghui
Shi, Jing
Wang, Xuelan
Lu, Yunxiang
Yan, Xiuhua
Wang, Guan
Jiang, Hualiang
Chen, Kaixian
Wang, Shudong
Xu, Yechun
Shen, Jingshan
Zhu, Weiliang
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (15) : 5607 - 5611
[17] Use of fluorous silica gel to separate fluorous thiol quenching derivatives in solution-phase parallel synthesis
Zhang, W
Curran, DP
Chen, CHT
[J]. TETRAHEDRON, 2002, 58 (20) : 3871 - 3875

← 1 2 →